Media stories about Evoke Pharma (NASDAQ:EVOK) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evoke Pharma earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 45.7752521054595 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of analysts have weighed in on EVOK shares. FBR & Co reaffirmed a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a research report on Monday, October 30th. ValuEngine cut Evoke Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Zacks Investment Research raised Evoke Pharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 12th. Seaport Global Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Friday, October 6th. Finally, Northland Securities reiterated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $9.00.

Evoke Pharma (NASDAQ:EVOK) traded down $0.10 during trading on Friday, hitting $2.31. The stock had a trading volume of 308,700 shares, compared to its average volume of 399,506. Evoke Pharma has a twelve month low of $1.42 and a twelve month high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same period last year, the company posted ($0.29) earnings per share. research analysts predict that Evoke Pharma will post -1 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.